<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="43968">Meropenem</z:chebi> was used in the treatment of 14 infectious complications in 11 patients including 8 with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> due to the <z:chebi fb="0" ids="35610">cytostatic</z:chebi> therapy, 1 with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 1 with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 1 with <z:hpo ids='HP_0011009'>acute</z:hpo> intermittent <z:mp ids='MP_0005654'>porphyria</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>At the moment of the <z:chebi fb="0" ids="43968">meropenem</z:chebi> use critical <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (less than 500 granulocytes per 1 ml) in 11 cases (79 per cent) was stated </plain></SENT>
<SENT sid="2" pm="."><plain>The drug was administered as intravenous infusions in a dose of 1 g every 8 hours for 4 to 41 days (the median of 11 days) </plain></SENT>
<SENT sid="3" pm="."><plain>9 out of the 14 infectious complications were cured (the body temperature normalized and <z:hpo ids='HP_0000001'>all</z:hpo> the <z:mp ids='MP_0001845'>inflammation</z:mp> foci were eliminated), among them 6 out of 8 pyocyanic <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Eradication of <z:mp ids='MP_0001795'>gram-negative</z:mp> bacteria was observed in 8 out of 10 cultures of the biological materials </plain></SENT>
<SENT sid="5" pm="."><plain>No toxic complications or electrolytic disorders due to the drug use were recorded </plain></SENT>
<SENT sid="6" pm="."><plain>The drug tolerance was good </plain></SENT>
</text></document>